Ein (CRP)Of 211 patients, 186 completed follow-up at year 1 (88.2 ) [19] and 173 sufferers (82.0 ) at year 2. No statistical variations were observed between baseline traits in 2-year completers versus non-completers. SUA decreased from mean 500 mol/L at baseline to 311 mol at 1 year and 324 mol/L at year 2, and 85.5 of sufferers were at target 360 mol at year 1 and 78.6 at year 2. Demographics and baseline characteristics are shown in Table 1 for all sufferers, and for those with and without flares during months 92 in years 1 and during year two. Individuals had been predominantly middle-aged males with a mean illness duration of about eight years, and 16.six had subcutaneous tophi. All individuals initiated or escalated ULT. Only 14.7 (31/211) of individuals had ever used ULT with allopurinol and none had utilized febuxostat, even though 78 had encounter ever with NSAID, and about half with each and every colchicine and prednisolone. Throughout the very first year, prescription of allopurinol decreased from 95.0 to 87.6 on account of switch to febuxostat and enhanced for febuxostat from three.five to 12.4 . Imply doses for allopurinol remained just below 300 mg and beneath 60 mg for febuxostat. Flare prophylaxis with colchicine was applied by 76.3 (161/211) of patients from baseline, with 72.three (146/202) applying colchicine at 1 month, 75.6 (146/193) at 2 months, 42.eight (80/189) at 3 months, and 14.five (27/187) at 6 months follow-up.Uhlig et al. Arthritis Study Therapy(2022) 24:Web page four ofTable 1 Baseline traits for all patients, and individuals with and without the need of a flare (percentage or imply with typical deviation (SD)Baseline 1 year follow-up (N = 186) N = 116 56.four (13.7) 56.3 (13.eight) 95.three 90.6 7.eight (7.six) 57.three 74.five 63.9 28.eight (four.5) three.7 (three.two) 30.four 11.1 61.8 38.6 16.six 14.7 78.0 53.two 45.7 500 (77) 14 (14) 96 (18) 78 (19) 7.7 12.0 31.three 49.0 73.4 eight.4 (1.6) 7.5 (five.5) 34.4 52.4 96.six 89.5 7.4 (6.eight) 61.7 76.7 69.8 28.five (4.6) three.3 (1.1) 36.eight ten.3 61.two 40.5 12.1 13.eight 74.3 43.eight 47.3 491 (81) 14 (13) 96 (17) 78 (18) six.0 16.4 29.three 48.3 73.7 8.1 (1.six) 7.1 (2.0) 33.eight 47.8 N = 70 57.6 (13.2) 92.9 92.four 9.six (9.3) 58.2 77.six 61.2 29.7 (4.6) four.five (three.four) 26.five 4.5 62.1 33.3 24.3 14.three 88.1 67.7 53.1 510 (78) 15 (15) 96 (19) 77 (18) 9.0 three.0 28.four 49.7 77.6 8.7 (1.4) 7.1 (two.1) 37.7 62.three 0.41 (0.44) 36 (10) 50 (ten) 61 (20) 72 (18) 0.38 0.013 0.96 0.60 0.06 0.35 0.006 0.91 0.015 0.51 0.52 0.30 0.51 0.10 0.64 0.89 0.23 0.09 0.013 0.15 0.16 0.90 0.34 0.017 0.92 0.028 0.Oleandomycin site 002 0.IL-2 Protein , Human (CHO) 46 0.PMID:24118276 12 0.46 0.90 0.71 0.042 16 25 65 102 151/206 208 207 72/209 110/210 7.8 12.five 32.0 47.7 69.3 8.2 (1.six) 7.1 (2.1) 31.0 50.0 0.34 (0.54) 40 (ten) 51 (10) 65 (19) 73 (17) 7.1 2.four 23.8 66.7 90.five eight.7 (1.1) 7.3 (1.9) 44.4 57.0 0.43 (0.69) 37 (12) 49 (10) 64 (21) 72 (15) 0.053 0.051 0.51 0.10 0.37 0.35 0.21 0.31 0.69 0.84 2 year follow-up (N = 173) N = 128 56.eight (13.9) 93.eight 92.0 eight.1 (eight.two) 58.3 76.4 64.1 29.2 (4.five) 3.7 (three.3) 29.1 10.9 63.0 38.six 14.1 14.8 77.six 50.4 45.1 496 (81) 14 (14) 95 (17) 78 (18) N = 45 57.1 (12.9) 97.eight 86.0 eight.8 (six.3) 66.7 76.7 73.eight 28.1 (four.7) three.eight (three.four) 41.9 two.4 57.1 38.1 22.2 6.7 86.0 56.1 52.four 504 (81) 17 (15) 99 (20) 75 (18) 0.88 0.45 0.25 0.62 0.34 0.96 0.25 0.18 0.91 0.12 0.12 0.61 0.96 0.20 0.16 0.23 0.53 0.41 0.58 0.21 0.11 0.27 0.10 No flare Months 92 Flare Months 92 p-value No flare Year two Flare Year two p-value N = 211 Age (years) Male Caucasian Illness duration (years) College education Married/cohabiting Functioning Body mas.